Chemours Stock Gets Lower EPS Estimate from Zacks Research

The Chemours Company (NYSE:CC – Free Report) – Investment analysts at Zacks Research cut their FY2026 earnings estimates for Chemours in a report issued on Monday, November 16th. Zacks Research analyst Team now expects that the specialty chemicals company will post earnings of $0.73 per share for the year, down from their previous forecast of $0.83. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.82 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.05 EPS, Q3 2027 earnings at $0.51 EPS, Q4 2027 earnings at $0.52 EPS, Q1 2028 earnings at $0.44 EPS, Q2 2028 earnings at $0.59 EPS and Q3 2028 earnings at $0.42 EPS.

Chemours (NYSE:CC – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The company had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.40 earnings per share.

Several other brokerages have also recently weighed in on CC. Barclays began coverage on Chemours in a research note on Monday, October 12th. They issued an “equal weight” rating and a $16.00 price target for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $16.00 target price on shares of Chemours in a report on Friday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Chemours in a report on Tuesday, November 3rd. JPMorgan Chase & Co. decreased their target price on shares of Chemours from $15.00 to $14.00 and set a “neutral” rating for the company in a research report on Monday, November 9th. Finally, Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target for the company. in a report on Tuesday, October 13th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Chemours currently has a consensus rating of “Hold” and an average target price of $17.36.

Check Out Our Latest Research Report on Chemours

Chemours Stock Down 6.4%

Shares of CC opened at $12.45 on Tuesday. The stock’s 50-day moving average price is $13.69 and its two-hundred day moving average price is $18.14. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67. The company has a market capitalization of $1.87 billion, a PE ratio of -12.20 and a beta of 1.47. The company has a current ratio of 1.81, a quick ratio of 0.98 and a debt-to-equity ratio of 24.25.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Shareholders of record on Monday, November 16th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 dividend on an annualized basis and a yield of 2.8%. Chemours’s dividend payout ratio is -34.31%.

Institutional Trading of Chemours

A number of large investors have recently bought and sold shares of CC. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours in the 2nd quarter worth about $34,000. Allworth Financial LP bought a new stake in shares of Chemours during the 2nd quarter valued at about $51,000. State of Wyoming bought a new stake in shares of Chemours during the 2nd quarter valued at about $67,000. Nykredit A S bought a new stake in shares of Chemours during the 2nd quarter valued at about $99,000. Finally, Sterling Capital Management LLC boosted its position in shares of Chemours by 839.3% during the 3rd quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after purchasing an additional 4,532 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Chemours

Here are a few of the latest headlines about CC:

  • Negative Sentiment: Analyst estimates were cut: Zacks Research lowered its forecasts for several quarters through 2028, including FY2026 EPS to $0.73 from $0.83 and Q4 2026 EPS to $0.05 from $0.11. The firm also rates Chemours “Strong Sell,” reinforcing concerns about its earnings outlook.
  • Negative Sentiment: Class-action litigation adds uncertainty: Shareholder lawsuits allege Chemours and some executives misrepresented Opteon demand. The claims relate to a reported 18.63% share decline following reduced 2026 guidance and concerns about an oversupplied refrigerant channel; the allegations have not been proven. Article: Chemours Investors Sued for Securities Fraud
  • Negative Sentiment: Investors face a December 7 lead-plaintiff deadline: Multiple law firms publicized the pending case and encouraged investors to seek lead-plaintiff status, keeping the allegations in the spotlight. Article: Chemours Securities Class-Action Deadline

Chemours Company Profile

(Get Free Report)

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO?) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.

Read More

Earnings History and Estimates for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.